Small-Scale Assays for Studying Dissolution of Pharmaceutical Cocrystals for Oral Administration
暂无分享,去创建一个
John Comer | Nikoletta Fotaki | Robert Price | Shyam Karki | N. Fotaki | R. Price | S. Karki | J. Comer | Karl J. Box | K. Box | Robert Taylor | Rebeca Ruiz | Robert Taylor | R. Ruiz | Rebeca Ruiz
[1] Jukka Rantanen,et al. Simultaneous UV imaging and raman spectroscopy for the measurement of solvent-mediated phase transformations during dissolution testing. , 2014, Journal of pharmaceutical sciences.
[2] J. W. Moore,et al. Mathematical comparison of dissolution profiles , 1996 .
[3] R. Bogner,et al. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability. , 2012, Journal of pharmaceutical sciences.
[4] C. Strachan,et al. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. , 2006, Journal of pharmaceutical and biomedical analysis.
[5] Orn Almarsson,et al. Performance comparison of a co-crystal of carbamazepine with marketed product. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[6] Narayan Variankaval,et al. Preparation and Solid-State Characterization of Nonstoichiometric Cocrystals of a Phosphodiesterase-IV Inhibitor and l-Tartaric Acid , 2006 .
[7] Jeanette T. Dunlap,et al. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. , 2004, Journal of the American Chemical Society.
[8] David R. Weyna,et al. Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics , 2014, Expert opinion on drug metabolism & toxicology.
[9] S. Kumar. Pharmaceutical Cocrystals: An Overview , 2017 .
[10] Orn Almarsson,et al. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. , 2003, Journal of the American Chemical Society.
[11] Kristyn Greco,et al. Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug. , 2011, Journal of pharmaceutical sciences.
[12] N. Fotaki,et al. Pharmaceutical characterisation and evaluation of cocrystals: Importance of in vitro dissolution conditions and type of coformer. , 2013, International journal of pharmaceutics.
[13] Aeri Park,et al. Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API , 2006, Pharmaceutical Research.
[14] P York,et al. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. , 2007, Advanced drug delivery reviews.
[15] Hywel D Williams,et al. Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.
[16] T. Rades,et al. The Influence of Pressure on the Intrinsic Dissolution Rate of Amorphous Indomethacin , 2014, Pharmaceutics.
[17] N. Rodríguez-Hornedo,et al. Pharmaceutical cocrystals and poorly soluble drugs. , 2013, International journal of pharmaceutics.
[18] John Comer,et al. The " dissolution" method: a low volume, in vitro apparatus for assessing the dissolution/precipitation behaviour of an active pharmaceutical ingredient under biorelevant conditions. , 2011, Analytical methods : advancing methods and applications.
[19] Yoshiki Hayashi,et al. Dissolution Improvement and the Mechanism of the Improvement from Cocrystallization of Poorly Water-soluble Compounds , 2008, Pharmaceutical Research.
[20] Mark McAllister,et al. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[21] A. Newman,et al. Pharmaceutical Cocrystals and Their Physicochemical Properties , 2009, Crystal growth & design.
[22] J. Dearden,et al. The intrinsic aqueous solubility of indomethacin , 2014 .
[23] R. Holm,et al. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility. , 2013, International journal of pharmaceutics.
[24] Sekhar Surapaneni,et al. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. , 2008, Journal of pharmaceutical sciences.
[25] Niklas Sandler,et al. Pharmaceutical co-crystals-an opportunity for drug product enhancement. , 2009, Expert opinion on drug delivery.
[26] Ashwini Nangia,et al. Nitrofurantoin-p-aminobenzoic acid cocrystal: hydration stability and dissolution rate studies. , 2011, Journal of pharmaceutical sciences.